Clinical trial
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
NCT00263588 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00263588 |
|---|---|
| Title | Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer |
| Official title | A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib |
| Enrollment | 242 |
| Start date | Dec 2, 2005 |
| Primary completion | Sep 25, 2007 |
| Completion | Mar 15, 2018 |
| First posted | Dec 9, 2005 |
| Last update posted | Dec 12, 2019 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, Greece, India, Italy, Japan, Poland, Spain and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: